OSE Pharma to participate to the Large & Midcap Event in Paris on October 7-8, 2015

Paris, September 29th, 2015, 5:45 pm - OSE Pharma SA (ISIN : FR0012127173 ; Mnemo : OSE), an immuno-oncology biotech company developing  a T specific immunotherapy at late clinical stage, announces its participation to the Large & Midcap Event to be held on October 7 and 8 in Paris' Palais Brongniart.

By participating to this event dedicated to European midcaps, OSE Pharma will specify its ambitions in the immuno-oncology area through the steps taken as part of its promising clinical results and its international clinical phase 3 study. The company intends to play a leading role in two priority areas through the development of Tedopi®, its flagship product: firstly, in monotherapy for lung cancer and secondly, through therapeutic combinations, an area where clear clinical findings are also expected.

"We are very pleased to participate to this edition of the Large & Midcap Event, a first for OSE Pharma, following our recent IPO. This forum gives us an opportunity to meet with European investors, all very interested in this revolutionary approach and paradigm shift that immunotherapy is causing in cancer care and where clinical results become a reality for patients", said Dominique Costantini, CEO of OSE Pharma.

ABOUT OSE PHARMA

OSE Pharma is a European cancer immunotherapy company with a multi-epitope technology named Memopi® that directs the body's immune system to generate a specific cytotoxic T response to prevent cancer cell growth.

OSE Pharma's lead product, Tedopi®, combines 10 "neo-epitopes" directed against five tumour associated antigens. In its most advanced application it is about to enter a pivotal Phase III study in patients with advanced non-small cell lung cancer (NSCLC) who express HLA-A2 and who have failed first line therapy. Tedopi® has orphan drug status in the USA and is considered as personalised medicine in Europe in HLA-A2 positive patients.

Furthermore, Tedopi® (OSE-2101) can be developed in Phase 2 in combination with other immunotherapy treatments or targeted therapy.

It is also considered in other oncology indications, also with HLA-A2 positive patients (ovaries, colon, prostate, breast).

Tedopi® targets five tumour associated antigens (TAA), selected because their presence is linked to a poor prognosis and the severity of various cancers. Tedopi® contains a total of ten optimised epitopes, or "neo- epitopes", designed on the binding of HLA-A2 and TCR. These neo-epitopes generate strong specific T cytotoxic responses that fight cancer and prevent tumour escape.

OSE Pharma is listed on Euronext Paris (ISIN : FR0012127173 ; Mnemo : OSE).
More information on www.osepharma.com

Follow us on Twitter @OSE_Pharma

Press contacts

Disclaimer:

This press release may expressly or implicitly contain forward-looking statements relating to OSE Pharma and its activity. Although OSE Pharma's management believes that the expectations reflected in these forward-looking statements are reasonable, investors are cautioned that such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from OSE Pharma's results, financial conditions, performance or achievements expressed, projected or implied by such information and forward-looking statements.
Other than as required by applicable law (article 223-1 et seq of the General Regulation of the AMF), OSE Pharma issues this press release at the date hereof and does not undertake any obligation to update or revise any forward-looking information or statements.
These risks and uncertainties include among other things, the uncertainties inherent in future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives,
For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Documents de Base filed with the AMF under number I. 14-056 on September, 17th 2014 and Chapter 2 "Risk Factors related to the Offer" in the prospectus approved by the AMF under number 15-078 on 6th March 2015, which can be found on the websites of the AMF (www.amf-france.org) and of OSE Pharma (www.osepharma.com).